|
|
|
市場調查報告書
癌症治療藥產品線：未來的標的療法
Oncology Pipelines: Is the Future Targeted Therapy?
|
本報告已在2011年12月21日停止出版。
製藥企業的癌症治療藥產品線快速增加，目前已有幾百種新藥正在開發當中。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. 總公司：Massachusetts State），針對癌症治療藥動向進行調查分析，並系統整理調查結果後出版報告書"Oncology Pipelines: Is the Future Targeted Therapy?"。
本報告書內容包括：目前的癌症治療動向、癌症治療藥當中全球銷售成績最好的主要產品、人體基因定序、RNA標的療法、未來市場發展預測等。內容綱要摘記如下：
實施概要
癌症治療的今日與明日
標的療法
癌症治療的領先企業
目前的現實：標的療法開發的困難
- 毒性及黑箱警告
- 針對個人的醫療
- AstraZeneca當初的絕望成為改革的開始
- Bristol-Myers Squibb擴大發展生物製劑
- Exelixis積極從事藥品發現及新藥研發
- Genentech/Roche領導癌症生物製劑的發展道路
- Genmab進行歐洲最大的產品交易
- GlaxoSmithKline靠著治療乳癌的「賀癌停（Herceptin）」持續發展
- ImClone雖面臨不斷的爭論，但仍因合法的暢銷藥持續穩健發展
- Novartis因小分子激脢抑制劑而具優勢
- Pfizer超越對小分子藥劑技術的歷史性信任，繼續前進
未來動向
專家評論
- 「癌症標的療法：針對個人醫療的動向」
- 「作為癌症標的療法之微RNA調節劑的發展潛力」
- 醫療學校
圖表
- 2015年的主力癌症治療藥
- 針對個人的標的療法
- 明日的RNA標的療法
Abstract
Introduction
Drug companies' cancer pipelines are bulging, and hundreds of new drugs are in
development-the modern equivalent of a gold rush. Remarkable successes have
been recorded with targeted oncology, but the treatment of more than 200 types
of cancer remains a daunting task. Today' s three principal modalities of
cancer treatment-surgery, radiotherapy, drug treatment-have begun to give way
to new targeted techniques. Genentech/Roche/Chugai' s Herceptin and ten other
blockbuster “targeted” therapies have shown that drugs designed to
interact with specifi c molecular targets can hit cancer where it hurts.
However, targeted therapies are no panacea; to continue advancing cancer
treatment, investigators must continue to improve their understanding of
specifi c drug targets and continue to explore gene regulation and protein
networks, to which targeted oncology therapies owe their existence.
Get the Answers You Need to Shape Your Strategy
- In 2007, there were 11 highly successful targeted cancer blockbusters.
Which drugs were they, and which blockbusters also carried a strong warning
label: namely, the dreaded “black box” authorized by the FDA?
- Amgen recently suffered several setbacks, including unfavorable trial
results from a Phase III trial of Vectibix in fi rst-line, metastatic
colorectal cancer. But Amgen still has upward of 60 ongoing development
programs. Why is this company still in need of a more vibrant pipeline?
- Bristol-Myers Squibb has a solid presence in targeted oncology drugs with
its blockbuster drug Erbitux. Which other drug in Bristol-Myers Squibb' s
portfolio represents a signifi cant achievement in the rational design of
drugs to overcome drug resistance in cancer?
- With Avastin, Herceptin, and Rituxan/MabThera, Genentech and Roche are on
track to rack up more than $11 billion in combined worldwide revenues in 2007.
Competition is on the way, however. Which companies have drugs in Phase III
trials for non-small-cell lung cancer? What are Genentech/Roche' s strategies
for expanding their prolifi c oncology franchise?
- For the last few years, ImClone has been sidetracked by legal issues; yet
ImClone still claims a legitimate cancer blockbuster: Erbitux, the fi rst
targeted cancer therapy approved for colorectal cancer. Why have unfavorable
results of Amgen' s Vectibix made clinicians, investigators, and investors
anxious about Erbitux' s future potential?
- Much excitement accompanied the completion of sequencing the human genome,
circa 2000. But the excitement soon gave rise to somber refl ection: the
sequencing itself did not immediately point the way to a bevy of new oncology
drugs. What work still needs to be done for human genome sequencing to realize
its promise of helping to provide personalized, targeted cancer therapies?
Scope
Scope
- Cancer therapy today and tomorrow: limitations of the three principal
modalities of current cancer treatment; addressing unmet needs; targeted
cancer therapy and personalized medicine; changes in the drug development
paradigm.
- Leaders in oncology: the world' s best-selling oncology drugs and the key
products in 11 leading oncology franchises.
- Oncology pipelines: Amgen' s woes; AstraZeneca' s disappointment;
Bristol-Myers Squibb' s expansion; Exelixis' s aggressive discoveries;
Genentech/Roche' s leading oncology franchise; Genmab' s waves;
GlaxoSmithKline' s oncological advances; ImClone' s legitimate blockbuster;
ImmunoGen' s “armed” technology; Novartis' s kinase inhibitors; Pfi
zer' s bandwagon-jumping.
- Waves of the future: human genome sequencing; the oncology gold rush; RNA
targeted therapies.
- Spectrum expert commentaries: two separate commentaries in which leading
oncology experts
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Cancer Therapy Today and Tomorrow
- Targeted Therapy-Hitting Cancer Where it Hurts
- Leaders in Oncology
- Today' s Reality-Diffi culties in Developing Targeted Therapies
- Toxicities and Black Box Warnings
- Personalized Medicine
- Murphy' s Law in Effect
- Key Products in Development
- AstraZeneca' s Initial Disappointment Gives Rise to Changes
- Bristol-Myers Squibb Expands into Biologics
- Exelixis Engages in Aggressive Drug Discovery and Development
- Third-Party Clinical Financing Vehicle
- Small-Molecule Kinase Inhibitors
- Genentech/Roche Lead the Way with Oncology Biologics
- Genmab Makes Waves with Largest European Product Deal Ever
- GlaxoSmithKline Advances into Herceptin' s Space in Breast Cancer
- ImClone Faces Ongoing Strife but Boasts a Legitimate Blockbuster
- ImmunoGen Innovates with Armed Antibody Technology
- Novartis Banks on Small-Molecule Kinase Inhibitors
- Pfi zer Moves Beyond Historical Reliance on Small-Molecule Drug
Technologies
- Waves of the Future
- Somber Refl ection on Human Genome Sequencing
- Mainstay Cancer Treatment Circa 2015
- Personalized Targeted Therapies
- Tomorrow' s RNA Targeted Therapies
Spectrum Expert Commentaries:
- “Targeted Oncology Therapy: Trend Toward Personalized
Treatment,” by David Z. Chang, M.D., Ph.D., Gastrointestinal Medical
Oncology & Immunology, The University of Texas, M.D. Anderson Cancer Center
- “The Potential of MicroRNA Modulators as Targeted Oncology
Therapies,” by Fabricio F. Costa, Ph.D., Cancer Biology and Epigenomics
Program, Children' s Memorial Research Center, Northwestern University' s
Feinberg School of Medicine, and Thomas Wurdinger, Ph.D., Molecular
Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital,
and Program in Neuroscience, Harvard Medical School
Tables:
- 1. Amgen' s Targeted Oncology Pipeline-Select Products, 2007
- 2. AstraZeneca' s Targeted Oncology Pipeline-Select Products, 2007
- 3. Bristol-Myers Squibb' s Targeted Oncology Pipeline-Select Products, 2007
- 4. Exelixis' s Targeted Oncology Pipeline-Select Products, 2007
- 5. Genentech and Roche' s Combined Targeted Oncology Pipeline-Select
Products, 2007
- 6. Genmab' s Targeted Oncology Pipeline-Select Products, 2007
- 7. GlaxoSmithKline' s Targeted Oncology Pipeline-Select Products, 2007
- 8. ImClone' s Targeted Oncology Pipeline-Select Products, 2007
- 9. ImmunoGen' s Targeted Oncology Pipeline-Select Products, 2007
- 10. Novartis' s Targeted Oncology Pipeline-Select Products, 2007
- 11. Pfi zer' s Targeted Oncology Pipeline-Select Products, 2007
Figures:
- 1. Leading Sites of New Cancer Cases and Deaths-2007 Estimates
- 2. Considerations for Successful Anticancer Drug Development
- 3. Best-Selling Oncology Products, 2006 and 2012
- 4. Leading Oncology Franchises-Key Products, 2006
- Expert Commentary. Epidermal Growth Factor Receptor Targeted Drugs
|
 |
